

<p>Informazione Regolamentata n. 0957-49-2026</p>	<p>Data/Ora Inizio Diffusione 21 Aprile 2026 07:29:04</p>	<p>Euronext Milan</p>
---	---	-----------------------

Societa' : DIASORIN

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio Vaccarone

Tipologia : 2.5

Data/Ora Ricezione : 21 Aprile 2026 07:29:04

Data/Ora Inizio Diffusione : 21 Aprile 2026 07:29:04

Oggetto : Communication on total amount of voting rights

Testo del comunicato

See in attachment.

DIASORIN: COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

Saluggia, April 21, 2026 – In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999 Diasorin (FTSE MIB: DIA) hereby communicates the total amount of the voting rights, together with the number of shares making up the share capital, as of April 20, 2026 (record date):

	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	120,133,843	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391 (regular enjoyment 01.01.2026) Current coupon: n. 21	23,855,339	23,855,339	-
Ordinary shares with increased voting rights – two votes per share ISIN IT0005188385 (regular enjoyment 01.01.2026) Current coupon: n. 21	250	500	-
Ordinary shares with increased voting rights – three votes per share ISIN IT0005188385 (regular enjoyment 01.01.2026) Current coupon: n. 21	32,092,668	96,278,004	-

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasorin.com



PRESS RELEASE ○○○

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com

Fine Comunicato n.0957-49-2026

Numero di Pagine: 4